SAB BIO Takes Novel Type 1 Diabetes Candidate to High-Stakes Investor Conferences

MIAMI, FL – March 02, 2026 – SAB Biotherapeutics, a clinical-stage company developing novel treatments for autoimmune diseases, announced today that its leadership will engage with the investment community at two prominent healthcare conferences in Miami this March. The presentations come at a critical juncture for the company as it advances its lead candidate, SAB-142, through a pivotal trial for Type 1 Diabetes (T1D), a disease on the cusp of a therapeutic revolution.

Management is scheduled for fireside chats at the Leerink Partners Global Healthcare Conference on March 9 and the Barclays 28th Annual Global Healthcare Conference on March 11. For a company like SAB BIO, these appearances are more than just calendar entries; they are crucial opportunities to articulate the value of its science, update stakeholders on clinical progress, and secure the financial footing necessary to navigate the high-cost, high-reward world of drug development.

The Investor Spotlight on a Potential T1D Breakthrough

The March conference circuit serves as a key platform for biopharmaceutical companies to command the attention of analysts and investors who shape market sentiment. For SAB Biotherapeutics, the timing is significant. The company is actively enrolling patients in its registrational Phase 2b clinical trial, named SAFEGUARD, for SAB-142, a therapy designed to modify the course of newly diagnosed Stage 3 T1D.

These forums allow management to provide color on clinical progress beyond formal press releases and filings. While the company has reported a strong cash position of $161.5 million as of late 2025—projecting a runway through 2028—the capital-intensive nature of late-stage clinical trials and potential commercialization means that maintaining investor confidence is paramount. The positive sentiment from the financial community, reflected in a consensus "Strong Buy" rating from many analysts, underscores the perceived potential of the company’s platform. The upcoming fireside chats will be a key test of that narrative.

Participation alongside industry heavyweights like Regeneron Pharmaceuticals and Guardant Health places SAB BIO in the spotlight, allowing it to differentiate its unique approach in a competitive environment. Investors will be keen to hear updates on the SAFEGUARD trial's enrollment progress and any forward-looking statements on the path to potential regulatory submission.

Beyond Insulin: A New Paradigm in Diabetes Care

For nearly a century, T1D management has centered on replacing the insulin the body can no longer produce. SAB Biotherapeutics is part of a new wave of innovation aiming not just to manage symptoms, but to intervene in the underlying autoimmune attack that causes the disease.

SAB-142 is a fully human anti-thymocyte immunoglobulin (hATG). In simple terms, it's a collection of highly specific antibodies designed to target and suppress the rogue T-lymphocytes that mistakenly destroy the insulin-producing beta cells in the pancreas. The goal is to preserve the patient's remaining beta cell function, thereby delaying or even preventing the progression to full insulin dependence.

This disease-modifying approach is currently being tested in the global SAFEGUARD trial, which dosed its first patient in December 2025. The study is enrolling newly diagnosed Stage 3 T1D patients across the U.S., Australia, and New Zealand, with European sites expected to follow. The company anticipates sharing top-line data from this crucial trial in the second half of 2027.

Confidence in the Phase 2b trial is bolstered by highly promising Phase 1 results. The initial study demonstrated a favorable safety profile and, critically, reported no instances of serum sickness or the formation of anti-drug antibodies. This is a significant differentiator from older rabbit-derived ATG therapies (rATG), which can cause immune reactions that limit their use. The clean safety profile of SAB-142 suggests it could potentially be re-dosed, a vital attribute for treating a chronic condition like T1D.

The Power of the Platform: Genetically Engineered Cattle

Underpinning SAB-142 is the company's proprietary Tc-Bovine™ technology—a groundbreaking platform that turns genetically engineered cattle into living bioreactors for producing human antibodies. These transchromosomic animals carry human DNA that allows their immune systems to generate a diverse and potent arsenal of fully human polyclonal antibodies in response to a specific antigen.

This innovative method circumvents two major historical challenges in antibody therapy: the limited supply of human plasma donors and the immunogenicity of antibodies derived from other animal species. The Tc-Bovine™ platform can rapidly produce large quantities of targeted, high-potency antibodies, a capability that was pressure-tested during pandemics and has shown preclinical efficacy against a range of formidable viruses, including SARS-CoV-2, MERS, and Ebola.

The platform's validity for human therapeutics is not merely theoretical. SAB Biotherapeutics previously advanced another candidate, SAB-301 for MERS, through a Phase 1 trial, which marked the first time antibodies from this platform were proven safe in humans. The company's ongoing engagement with the FDA's Center for Veterinary Medicine further legitimizes the regulatory pathway for this novel production system.

Navigating a Crowded and Competitive Field

SAB Biotherapeutics does not operate in a vacuum. The race to develop disease-modifying therapies for T1D is heating up. In 2022, the FDA approved Tzield (teplizumab), the first-ever therapy to delay the onset of Stage 3 T1D. Other treatments, such as the JAK inhibitor Baricitinib and the T-cell modulator Abatacept, have also shown promise in preserving beta cell function in clinical studies. Major pharmaceutical players like Eli Lilly are also advancing their own candidates through late-stage trials.

In this dynamic landscape, SAB-142's differentiation is key. Its potential for a superior safety profile and the ability to be re-dosed without triggering an adverse immune response could offer a significant clinical advantage for long-term disease management. As the company presents its case to investors, highlighting these unique attributes will be crucial to stand out in a field filled with both promise and intense competition.

As the management team takes the stage in Miami, they will be speaking to more than just investors. Their updates represent the latest chapter in a broader scientific quest to redefine the future of Type 1 Diabetes care. For the millions of people living with the disease, the progress of novel therapies like SAB-142 offers a tangible sense of hope that a future beyond daily insulin injections may be within reach. The road from a clinical-stage candidate to an approved therapy is long and fraught with challenges, but the data and technology SAB Biotherapeutics brings to the table ensure that its journey will be watched with great interest.